Sclerotherapy with 3% polidocanol foam for third- and fourth
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
In Italy, colorectal surgery has been strongly affected with the vast majority (90%) of operations treating benign diseases, with an estimated overall 12-week cancellation rate of 72%. Sclerotherapy with 3% polidocanol foam can be used for third- and fourth-degree hemorrhoids as “bridge treatment” during the COVID-19 pandemic.

Little is known on how to best manage patients with benign diseases and the consequences this interruption of care will have in post-pandemic times. Proctology diseases have social, psychological, and healthcare repercussions for their high incidence and great impact on the quality of life.

Investigators decided to treated 10 urgent cases affected from III- and IV-degree hemorrhoids with 3% polidocanol foam in an attempt to reduce hemorrhoidal symptoms while waiting for surgery so-called “bridge treatment”.

During the follow-up, no complications have occurred, and all patients had resolution of bleeding and pruritus with a mean VAS of 1.

This treatment could reduce the bleeding that is the main symptom from which patients suffer and for which they underwent proctological evaluation and surgery.

According to the preliminary experience in the impossibility of accessing the surgery during the COVID-19 pandemic, ST could be considered as the treatment of choice in those patients who are suffering from grade III- and IV-degree hemorrhoids while waiting for surgery.

International Journal of Colorectal Disease